Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
Earnings Data
Report Date
Feb 24, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
1.92Last Year’s EPS
1.26Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call revealed strong financial performance driven by robust revenue growth from key subcutaneous therapies and strategic acquisitions. However, there are some challenges with collaboration revenue declines and pending acquisitions. Overall, the positive aspects significantly outweigh the negatives.Company Guidance
Record Royalty Revenue
Halozyme reported a record royalty revenue of $236 million, a 52% increase year-over-year, contributing to total revenue of $354 million, which is a 22% growth year-over-year.
Strong Performance of Core Subcutaneous Therapies
The quarter's performance was driven by DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo, with DARZALEX achieving a 20% operational increase to $3.7 billion in sales.
Increased Full Year 2025 Guidance
Halozyme raised its full-year 2025 guidance, projecting total revenue of $1.3 billion to $1.375 billion, reflecting 28% to 35% growth over 2024.
Acquisition of Elektrofi
Halozyme announced the acquisition of Elektrofi to enable at-home administration of biologic therapies, aiming to expand its portfolio and patient-centric solutions.
Successful Launch of New Products
OCREVUS ZUNOVO, Tecentriq Hybreza, and OPDIVO Qvantig with ENHANZE have shown strong uptake and contribute to the future growth trajectory.
Strong Cash Flow and Share Repurchases
Year-to-date, $342 million of shares were repurchased, with robust cash flow allowing for balanced capital allocation.
HALO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HALO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 03, 2025 | $66.20 | $68.05 | +2.79% |
Aug 05, 2025 | $60.81 | $62.32 | +2.48% |
May 06, 2025 | $59.38 | $70.14 | +18.12% |
Feb 18, 2025 | $57.90 | $57.77 | -0.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Halozyme Therapeutics (HALO) report earnings?
Halozyme Therapeutics (HALO) is schdueled to report earning on Feb 24, 2026, After Close (Confirmed).
What is Halozyme Therapeutics (HALO) earnings time?
Halozyme Therapeutics (HALO) earnings time is at Feb 24, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HALO EPS forecast?
HALO EPS forecast for the fiscal quarter 2025 (Q4) is 1.92.